文献速递白血病

DHX15与HNRNPL、RBM33协同调控AML1-ETO9a剪接促进AML1-ETO阳性急性髓系白血病进展

DHX15 affects AML1-ETO9a splicing together with HNRNPL, RBM33 in AML1-ETO-positive acute myeloid leukaemia.
PubMed 文献 · Br J Haematol · 2026-07-12

本研究探讨RNA解旋酶DHX15在AML1-ETO9a剪接及AML进展中的作用。临床数据显示DHX15高表达与AE9a/AE丰度增加及AE阳性AML患者不良预后相关。DHX15敲低可抑制细胞增殖、诱导S/G2期阻滞并延长荷瘤小鼠总生存,且DHX15结合AE与AE9a转录本,HNRNPL与RBM33选择性结合AE9a转录本。

要点

  • DHX15高表达与AE阳性AML患者AE9a/AE丰度升高及不良预后相关
  • DHX15敲低抑制细胞增殖、诱导S/G2期阻滞并延长荷瘤小鼠生存
  • DHX15与HNRNPL、RBM33形成调控复合物参与AE9a剪接

核心结论

  • DHX15、HNRNPL与RBM33与AE9a剪接相关,并可能促进AE阳性AML的白血病进展。

研究设计与样本

  • 基础与临床结合研究,涉及AE阳性AML患者样本、Kasumi-1细胞及AE阳性白血病荷瘤小鼠模型。

主要发现

  • AE阳性AML患者中DHX15高表达与AE9a/AE丰度增加及不良预后相关。
  • DHX15敲低在体外抑制细胞增殖并诱导S/G2期细胞周期阻滞,在体内延长AE阳性白血病荷瘤小鼠总生存。
  • DHX15敲低降低AE与AE9a表达,RNA免疫沉淀显示DHX15结合AE与AE9a转录本。
  • RNA pull-down显示HNRNPL与RBM33选择性结合AE9a转录本,三维结构预测提示DHX15、HNRNPL与RBM33形成调控复合物。
  • AE阳性AML样本中HNRNPL与RBM33表达与AE9a水平正相关,敲低HNRNPL与RBM33降低Kasumi-1细胞AE9a表达。

临床怎么用

  • DHX15高表达或可作为AE阳性AML不良预后的参考标志物,但需进一步验证。
  • 靶向DHX15或其与HNRNPL、RBM33的剪接调控复合物可能成为AE阳性AML的潜在治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The AML1-ETO (AE) fusion gene, resulting from t(8;21)(q22;q22), represents a prevalent subtype of acute myeloid leukaemia (AML). Retention of exon 9a between exon 8 and 9 of the ETO (RUNX1 Partner Transcriptional Co-Repressor 1, also name RUNX1T1) gene generates the oncogenic AML1-ETO9a (AE9a) splice variant. Here, we uncover the potential involvement of RNA (ribonucleic acid) helicase DHX15 (DEAH-box helicase 15) in AE9a splicing and AML progression. Clinically, higher expressed DHX15 is associated with increased AE9a/AE abundance and poor outcomes in AE-positive (AE+) AML patients. DHX15 knockdown impaired cell proliferation, induced S/G2 cell-cycle arrest in vitro and prolonged overall survival in AE+ leukaemia-bearing mice in vivo. In addition, DHX15 knockdown reduced AE and AE9a expression, and RNA immunoprecipitation revealed DHX15 bound to AE and AE9a transcripts and RNA pull-down assay showed a selective interaction of HNRNPL and RBM33 with AE9a transcripts. Three-dimensional structure prediction suggests a sophisticated regulatory complex formation involving DHX15, HNRNPL (heterogeneous nuclear ribonucleoprotein L) and RBM33 (RNA binding motif protein 33). Further, HNRNPL and RBM33 gene expression positively correlated with AE9a levels in AE+ AML samples. Downregulation of HNRNPL and RBM33 reduced AE9a expression in Kasumi-1 cells. Collectively, our findings support an association between DHX15, HNRNPL, RBM33 and AE9a splicing and suggest their contribution to leukemogenic progression in AE+ AML.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Liu Q, Wang X, Fan J, et al. DHX15 affects AML1-ETO9a splicing together with HNRNPL, RBM33 in AML1-ETO-positive acute myeloid leukaemia. Br J Haematol. 2026. PMID: 42438298. doi:10.1111/bjh.70658

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。